Sign up to save your podcasts
Or
Share New drug looks very promising in high risk chronic lymphocytic leukaemia
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
New drug looks very promising in high risk chronic lymphocytic leukaemia
ATLANTA, GEORGIA—The new tyrosine kinase ibrutinib has shown “profound activity” in patients with chronic lymphocytic leukaemia—according to research presented at the American Society of Hematology annual meeting. Dr Jan Burger from the MD Anderson Cancer Center…
View all episodes
By AudioMedica.comATLANTA, GEORGIA—The new tyrosine kinase ibrutinib has shown “profound activity” in patients with chronic lymphocytic leukaemia—according to research presented at the American Society of Hematology annual meeting. Dr Jan Burger from the MD Anderson Cancer Center…